| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6819315 | Psychoneuroendocrinology | 2015 | 11 Pages |
Abstract
In conclusion, paroxetine seems to interfere with HPA-axis dysregulation, reflected in significant overall decreases in BCL and AUC during treatment. Paroxetine appears to decrease HPA-axis set-point in MDD, which might result in increased HPA-axis activity over time, which is further improved when patients achieve remission (ISRCTN register nr. ISRCTN44111488).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Henricus G. Ruhé, Sharina J. Khoenkhoen, Koen W. Ottenhof, Maarten W. Koeter, Roel J.T. Mocking, Aart H. Schene,